Suggested remit: To appraise the clinical and cost effectiveness of eflornithine within its marketing authorisation for treating high-risk neuroblastoma with complete or partial response after immunotherapy.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 4060
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Bristol Technology Assessment Group, University of Bristol
Stakeholders
- Companies sponsors
- Norgine (eflornithine)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Gene People
- Solving Kids’ Cancer UK
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 April 2025 | Committee meeting |
| 03 April 2025 | Declaration of interests |
| 17 March 2025 | Eflornithine has not yet received regulatory approval, so the committee meeting on 3 April 2025 will be held in private. |
| 06 September 2024 | Invitation to participate |
| 19 July 2024 | Please note that following conversations between NICE and the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early September 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-November 2024. Draft scope consultation will be issued in late July 2024. |
| 09 November 2022 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy. Please note that following on from information received from the company, the timelines for this appraisal will be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any developments and will update interested parties as and when the situation changes. |
| 17 March 2022 - 14 April 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 17 March 2022 | In progress. Scoping commenced |
| 28 January 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual